Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2013

01-01-2013 | Breast Oncology

Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000

Authors: Montserrat Solá, MD, José A. Alberro, MD, Manuel Fraile, MD, Pilar Santesteban, MD, Manuel Ramos, MD, Rafael Fabregas, MD, Antonio Moral, MD, Blas Ballester, MD, Sergi Vidal, MD

Published in: Annals of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Background

It has been suggested that selective sentinel node (SN) biopsy alone can be used to manage early breast cancer, but definite evidence to support this notion is lacking. The aim of this study was to investigate whether refraining from completion axillary lymph node dissection (ALND) suffices to produce the same prognostic information and disease control as proceeding with completion ALND in early breast cancer patients showing micrometastasis at SN biopsy.

Methods

This prospective, randomized clinical trial included patients with newly diagnosed early-stage breast cancer (T < 3.5 cm, clinical N0, M0) who underwent surgical excision as primary treatment. All had micrometastatic SN. Patients were randomly assigned to one of the two study arms: complete ALND (control arm) or clinical follow-up (experimental arm). Median follow-up was 5 years, recurrence was assessed, and the primary end point was disease-free survival.

Results

From a total sample of 247 patients, 14 withdrew, leaving 112 in the control arm and 121 in the experimental arm. In 15 control subjects (13 %), completion ALND was positive, with a low tumor burden. Four patients experienced disease recurrence: 1 (1 %) of 108 control subjects and 3 (2.5 %) of 119 experimental patients. There were no differences in disease-free survival (p = 0.325) between arms and no cancer-related deaths.

Conclusions

Our results strongly suggest that in early breast cancer patients with SN micrometastasis, selective SN lymphadenectomy suffices to control locoregional and distant disease, with no significant effects on survival.
Literature
1.
Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17:1720–6.PubMed
2.
Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229:536–41.PubMedCrossRef
3.
Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91:1245–52.PubMedCrossRef
4.
Fant JS, Grant MD, Knox SM, Livingston SA, Ridl K, Jones RC, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126–30.PubMedCrossRef
5.
Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30.PubMedCrossRef
6.
Guenther JM, Hansen NM, DiFronzo LA, Giuliano AE, Collins JC, Grube BL, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138:52–5.PubMedCrossRef
7.
Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206:261–8.PubMedCrossRef
8.
Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Nolthenius-Puylaert MCT, Nieuwenhuijzen GA. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat. 2010;127:195–203.PubMedCrossRef
9.
Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2012;131:819–25.PubMedCrossRef
10.
Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241:152–8.PubMed
11.
Gobardhan PD, Elias SG, Madsen EV, Bongers V, Ruitenberg HJM, Perre CI, et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol. 2011;18:1657–64.PubMedCrossRef
12.
Yegiyants S, Romero LM, Haigh PI, DiFronzo LA. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node. Arch Surg. 2010;145:564–9.PubMedCrossRef
13.
Fleming ID, Cooper JS, Henson DE. AJCC cancer staging manual. 4th ed. Philadelphia: Lippincott-Raven; 1997.
14.
Greene FL, Page DL, Fleming ID. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
15.
Neville AM, Price KN, Gelber RD, Goldhirsh A. Axillary node micrometastases and breast cancer. Lancet. 1991;337:1110.PubMedCrossRef
16.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357–65.PubMedCrossRef
17.
Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;22:394–9.CrossRef
18.
Schreiber RH, Pendas S, Ku NN, Reintgen DS, Shons AR, Berman C, et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel node. Ann Surg Oncol. 1999;6:95–101.PubMedCrossRef
19.
Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28.PubMedCrossRef
20.
Cronin-Fenton DP, Ries LA, Clegg LX, Edwards BK. Rising incidence rates of breast carcinoma with micrometastatic lymph node involvement. J Natl Cancer Inst. 2007;99:1044–9.PubMedCrossRef
21.
22.
Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–8.PubMedCrossRef
23.
Saidi RF, Dudrick PS, Remine SG, Mittal VK. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am Surg. 2004;70:101–5.PubMed
24.
Leidenius MHK, Vironen JH, Riihela MS, Krogerus LA, Toivonen TS, von Smitten KAJ, et al. The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Eur J Surg Oncol. 2005;31:13–8.PubMedCrossRef
25.
Fraile M, Rull M, Julian FJ, Fuste F, Barnadas A, Llatjos M, et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol. 2000;11:701–5.PubMedCrossRef
26.
Cserni G, Amendoira I, Apostolikas N, et al.; European Working Group for Breast Screening Pathology. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003;39:1654–67.
27.
Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruneri G, Paganelli G, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103:492–500.PubMedCrossRef
28.
Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001;92:1378–84.PubMedCrossRef
29.
Ganaraj A, Kuhn JA, Jones RC, Grant MD, Andrews VR, Knox SM, et al. Predictors for non sentinel involvement in breast cancer patients with micrometastases in the sentinel node. Proc Bayl Univ Med Cent. 2003;16:3–6.PubMed
30.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. J Am Med Assoc. 2011;305:569–75.CrossRef
31.
32.
Metadata
Title
Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000
Authors
Montserrat Solá, MD
José A. Alberro, MD
Manuel Fraile, MD
Pilar Santesteban, MD
Manuel Ramos, MD
Rafael Fabregas, MD
Antonio Moral, MD
Blas Ballester, MD
Sergi Vidal, MD
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2569-y

Other articles of this Issue 1/2013

Annals of Surgical Oncology 1/2013 Go to the issue

Healthcare Policy and Outcomes

Multimedia Support for Improving Preoperative Patient Education: A Randomized Controlled Trial Using the Example of Radical Prostatectomy

Breast Oncology

Oncological Safety of Autologous Lipoaspirate Grafting in Breast Cancer Patients: A Systematic Review

Hepatobiliary Tumors

Up-front Hepatic Resection for Metastatic Colorectal Cancer Results in Favorable Long-term Survival

Hepatobiliary Tumors

A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability

Neuro-Oncology

The Current Role of Surgery in Metastatic Spine Disease: A New Era

Head and Neck Oncology

Is Neck Dissection Necessary After Induction Plus Concurrent Chemoradiotherapy in Complete Responder Head and Neck Cancer Patients with Pretherapy Advanced Nodal Disease?